Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

home / precision-medicine / expanding-options-for-relapsed-refractory-gastrointestinal-stromal-tumors

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

Challenges Associated with GIST Management

EP. 1: Challenges Associated with GIST Management

Targeted Oncology
July 1st 2020

Watch

Mutations in Gastrointestinal Stromal Tumors

EP. 2: Mutations in Gastrointestinal Stromal Tumors

Targeted Oncology
July 1st 2020

Watch

GIST Mutations: Are Some Worse Than Others?

EP. 3: GIST Mutations: Are Some Worse Than Others?

Targeted Oncology
July 1st 2020

Watch

GIST Mutations: Treatment Decision Factors

EP. 4: GIST Mutations: Treatment Decision Factors

Targeted Oncology
July 1st 2020

Watch

Standard Treatment Options for Metastatic GIST

EP. 5: Standard Treatment Options for Metastatic GIST

Targeted Oncology
July 1st 2020

Watch

Unmet Needs in GIST: Toxicity Management

EP. 6: Unmet Needs in GIST: Toxicity Management

Targeted Oncology
July 1st 2020

Watch

Treatment Options After Relapse

EP. 7: Treatment Options After Relapse

Targeted Oncology
July 1st 2020

Watch

Recently Approved Targeted Therapy for Fourth-Line GIST

EP. 8: Recently Approved Targeted Therapy for Fourth-Line GIST

Targeted Oncology
July 1st 2020

Watch

INTRIGUE Trial Overview

EP. 9: INTRIGUE Trial Overview

Targeted Oncology
July 1st 2020

Watch

NAVIGATOR Trial Overview

EP. 10: NAVIGATOR Trial Overview

Targeted Oncology
July 1st 2020

Watch

Advanced GIST: The Impact of Newly Approved Agents

EP. 11: Advanced GIST: The Impact of Newly Approved Agents

Targeted Oncology
July 1st 2020

Watch